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Background: Spontaneous, nontraumatic intracerebral hemorrhage (ICH) is a subtype of stroke that causes a great
amount of disability and economic and social burden. This is particularly true in developing countries where it
accounts for between 20% and 50% of all strokes. Pharmacological and surgical interventions have been attempted
to reduce the mortality and disability caused by ICH, with unsuccessful results. Recently, the use of fluoxetine in
addition to physical rehabilitation has been proven useful to improve motor recovery following cerebral infarct. The
purpose of this study is to test whether a 3-month treatment with fluoxetine enhances motor recovery in
nondepressed patients with acute intracerebral hemorrhage.
Methods/design: Our study is a randomized, double-blind, placebo-controlled, multicenter clinical trial. We will
recruit 86 patients with intracerebral hemorrhage of both sexes, aged >18 years, from four Mexican hospitals. The
patients will receive either 20 mg of fluoxetine or a placebo once daily for 90 days. The primary outcome is the
mean change in the Fugl-Meyer Motor Scale score between inclusion (day 0) and day 90. The secondary outcomes
will be changes in the Barthel Index, the Modified Rankin scale and the National Institutes of Health stroke scale.
The outcomes will be measured at day 42 ± 7days and at day 90, for a total of four visits with each subject
(at screening and at 0, 42 and 90 days).
Discussion: Current guidelines recommend early supported hospital discharge and home-based rehabilitation
programs as the only cost-effective intervention to aid the recovery of patients with intracerebral hemorrhage.
Nevertheless, such interventions are dependent on available resources and funding, which make them very difficult
to implement in developing countries. We believe that the identification of a helpful pharmacological intervention
to aid the motor recovery of these patients will constitute a breakthrough that will have a major impact in reducing
the burden of disease caused by this subtype of stroke worldwide, especially in the developing world.
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Spontaneous, nontraumatic intracerebral hemorrhage (ICH)
is a significant cause of morbidity and mortality worldwide,
and no treatment has been proven effective [1]. Each year,
approximately 1 million people suffer from ICH [2], which
causes a great amount of disability and economic and social
burden. This is particularly true in developing countries
where ICH accounts for between 20% and 50% of all
strokes [3]. Hispanic Americans and especially Mexican
Americans have been shown to have an increased risk of
ICH compared with non-Hispanic whites [4]. The higher
prevalence of ICH appears to be very similar in Hispanic
patients living in Mexico and in the USA [5]. Despite these
data, it is not clear whether this excess in incidence is due
to differences inherent to ethnicity, or due to other differ-
ences in the disease pathogenesis.
Several therapeutic approaches have been attempted to
reduce the burden in terms of death and disability from
ICH, including pharmacological and surgical interventions,
but trials have been largely unsuccessful [6]. These failures
have encouraged a focus on management in intensive care
units and physical rehabilitation as the mainstream ap-
proaches to reduce mortality and disability, respectively [7].
Recently, the use of antidepressant drugs as an adjunctive
treatment to augment recovery in stroke patients has been
studied in small clinical trials [8-11]. In 2011, Chollet and
colleagues [12] tested adjunctive treatment with fluoxetine
in addition to physical rehabilitation to improve motor re-
covery from cerebral infarct (CI), with excellent results.
Subsequent evidence indicated that this improvement is
persistent through time [13].
It is thus necessary to elucidate the relative importance
and potential benefits of the use of fluoxetine in ICH pa-
tients, so that this drug can play a role as an adjunctive
therapy to aid the motor recovery of ICH patients, similar
to CI patients.
This study will be the first reported randomized,
double-blind, placebo-controlled clinical trial of the use
of fluoxetine for motor recovery in patients with ICH.
The main purpose of this study is to test whether a
three-month treatment with fluoxetine enhances motor




The main objectives of this trial are to (1) compare the
magnitude of motor recovery, measured with the Fugl-
Meyer Motor Scale (FMMS), in patients receiving fluox-
etine with that of patients receiving placebo, and (2)
establish the relationship between motor recovery and
functional recovery as measured with the Barthel index(BI), the modified Rankin scale and the National Insti-
tutes of Health stroke scale (NIHSS).
Hypothesis
We hypothesize that the mean change in FMMS between
inclusion (day 0) and day 90 will be significantly higher in
the patients receiving fluoxetine compared with those re-
ceiving placebo.
Study design and period
This study is a 12-week randomized, double-blind, placebo-
controlled, multicenter trial at four Mexican hospitals.
Figure 1 shows the schematic flow of the study.
Study groups
The study will include the following two arms: the
fluoxetine group (treatment arm) and the placebo group
(control arm).
Population
The subjects will be patients of both sexes with acute
ICH and ages above 18 years.
Eligibility criteria
Inclusion Criteria
1. Men and women ages ≥ 18 years
2. Individuals who meet one of the following criteria:2.1. Patients who had an acute intracerebral
hemorrhage within the past 10 days causing
hemiparesis or hemiplegia
2.2. Fugl-Meyer motor scale (FMMS) scores ≤ 55
3. Written, informed consent for participation in the trial
Exclusion Criteria
1. Severe post-stroke disability (National Institutes of
Health stroke scale [NIHSS] score >20)
2. Premorbid disability, evidenced by residual motor
deficit from a previous stroke
3. Comprehension deficits or severe aphasia
4. Previous diagnosis of depression or one of the
following:
4.1. Hospital anxiety and depression scale (HAD)
score ≥11 points
4.2. Taking antidepressant drugs two weeks before
inclusion
5. Taking neuroleptic drugs or benzodiazepines 2
weeks before inclusion
6. Other major diseases with life expectancy ≤ 3 months.
Withdrawal Criteria
1. Detection of eligibility violations
Figure 1 Flowchart of the fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH) clinical trial.
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3. Use of any medication or treatment during the trial
that could affect the study results
4. Occurrence of a serious adverse event
4.1.Subject has an acute reaction (allergy, shock) to
the investigational product
4.2.Subject develops depression, evidenced by HAD
score ≥11 points at Visit 2
5. Subject withdraws consent or is uncooperative
The patients withdrawn after randomization will be
followed for outcomes
Interventions
Participating subjects assigned to either the treatment
group or the placebo group will be instructed to take a pill
of fluoxetine (20 mg) or placebo once daily for 90 days. Flu-
oxetine and placebo tablets will be identical in form, color,
odor and packaging.
Concomitant treatments and forbidden drugs
The product name, use, dosage and duration of all medica-
tions used by the patients during their hospital stay and
follow-up will be recorded. Only the use of antidepressants
will be prohibited.
Sample size calculation
A sample size of 35 in each group will be sufficient to de-
tect a clinically important difference of 14.5 points on the
FMMS, assuming a standard deviation of 21.3 FMMS
points on the basis of the findings of the fluoxetine in
motor recovery of patients with acute ischaemic stroke
(FLAME) trial [12], using a two tailed t-test of the differ-
ence between means, a power of 80%, and a significancelevel of 5%. This number has been increased to 44 per
group (total of 88), to allow for a predicted 20% loss to
follow-up.
The formula for the sample size for comparison of two
means (two-sided) is as follows:
n ¼ 2σ




δ = size of difference of clinical importance = 14.5
σ = standard deviation of the primary outcome vari-
able = 21.3
n ¼ 2  21:3
2 1:96þ 0:84ð Þ2
14:52
≈35
Adjusted for 20% patients lost to follow-up:
nc ¼ n1 l ≈44
l = expected frequency of patients lost to follow-up = 0.20
Randomization method
A pharmaceutical laboratory (Psicofarma™ S.A. de C.V.)
will be responsible for the manufacture and randomization
of the investigational product, which will be achieved
using a web-based randomization program. This program
will be set to assign participants equally to each site at a
ratio of 1:1.
Each of the sites will be assigned 22 participants. The
manufacturer will then deliver the pre-randomized bottles
Table 1 Study schedule of fluoxetine for motor recovery











Inclusion/exclusion criteria check •
Vital signsb • • •




Coagulation testsf • •





Date of BCT •
Volume of the hemorrhageh •
Localization of the hemorrhage •
Concomitant medication • • • •
Adverse event • •
NHISS • • •
Depression Scale • • •
Fugl-Meyer Motor Scale • • •
Patient’s rehabilitation log • •
Barthel Index • • •
Modified Rankin Scale • • •
Pill count • •
aAge, gender, educational level, marital status, occupational status, date of
birth, contact address and telephone number. bBlood pressure (mmHg), pulse
(beats/minute) and body temperature (°C). cDiabetes Mellitus, hypertension,
dyslipidemia. dHemoglobin, hematocrit, red blood cell count, white blood cell
count, platelet count, blood urea, nitrogen/creatinine ratio, fasting plasma
glucose. eTotal cholesterol (mg/dl), high-density lipoprotein cholesterol
(mg/dl), low-density lipoprotein cholesterol (mg/dl), very low-density
lipoprotein cholesterol (mg/dl), triglyceride (mg/dl). fInternational Normalized
Ratio, prothrombin time, activated partial thromboplastic time. gTrauma,
Drugs, bleeding disorder, exercise. hABC/2 method. BCT, Brain Computed
Tomography; NIHSS, National Institutes of Health Stroke Scale.
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center.
Study subjects who satisfy the eligibility criteria at each
recruiting center will receive the investigational product
corresponding to a consecutive number assigned according
to their entrance to the study.
Blinding
Both the investigator and the subject will be blinded to the
assignment of the study drugs. The manufacturer of the
tablets will label the investigational drugs by the ran-
domization code number. The labeled experimental prod-
ucts will be provided to the recruiting centers by the
manufacturer. An envelope containing all randomization
codes will be delivered to the principal investigator and
will be kept sealed until the conclusion of the trial.
Recruitment
Participants will be recruited at the emergency departments
at four Mexican hospitals:
The Centenario Hospital ‘Miguel Hidalgo’ (located in
Aguascalientes, a midsized city in central México), the
Instituto Nacional de Neurología y Neurocirugía (located
in Mexico City), the Antiguo Hospital Civil de Guadalajara
‘Fray Antonio Alcalde’ (located in Guadalajara, a major
city in western Mexico) and the Hospital Regional de Alta
Especialidad ‘Dr. Juan Graham Casassus’ (located in
Villahermosa, a midsized city in the south of Mexico).
Study schedule
The measurements that will be carried out at each visit
are listed in Table 1.
Measurement tools
Questionnaires
The fugl-meyer assessment (FMA)
The Fugl-Meyer assessment (FMA) [14] is a stroke-specific,
performance-based impairment index. It is designed to as-
sess motor functioning, balance, sensation and joint func-
tioning in hemiplegic post-stroke patients. Each of the five
FMA domains can be separated to test a specific construct.
The motor domain (FMMS) includes items assessing
movement, coordination and reflex action of the shoulder,
elbow, forearm, wrist, hand, hip, knee, and ankle. We will
use the FMMS to assess the motor recuperation of patients
in this study.
The Barthel index
The Barthel index [15] is a widely used measure of func-
tional disability. The index was developed for use in the re-
habilitation of patients with stroke. This index measures
the extent to which someone can function independently
and has the mobility necessary for their daily life activities.We will use the BI to establish the relationship between
motor recovery (FMMS) and functional recovery.
The hospital anxiety and depression scale
The hospital anxiety and depression scale (HAD) [16] is a
scale widely used to evaluate anxiety and depression in hos-
pitalized patients and has been validated in Spanish [17]. It
consists of 14 items: the odd items represent the anxiety
subscale and the even items the depression subscale, and
both are scored between 0 and 3. The total score is
Marquez-Romero et al. Trials 2013, 14:77 Page 5 of 7
http://www.trialsjournal.com/content/14/1/77obtained by the summation of all items in each subscale.
The severity of the condition increases with the score. In a
validation study by Abent et al. [18], the use of the HAD
scale resulted in a sensitivity of no less than 91.7 (specificity:
65.3) using the optimum threshold score of 11. The authors
concluded that although there were no substantial differ-
ences in the performances of the four depression rating
scales that they studied, the HAD scale was preferred in
screening for post-stroke depression because it requires the
least amount of time to administer. Thus, we will use the
HAD to rule out depression in the patients enrolling and
participating in this study.
Compliance
All subjects will be asked to return the remaining tablets at
their next visit. The rate of compliance (percentage) will be
calculated on the basis of the returned tablets.
Compliance (%) = 100 - returned tablets/expected in-
take × 100.
Investigational drugs will be distributed in packs of 50
at each visit.
50 = 1 times/day × 7 days/week × 6 weeks/visit + 8 extras.
Outcomes
Both primary and secondary end points will be measured at
each visit according to the study schedule (Table 1).
Primary outcome
The primary outcome is the mean change in FMMS score
between inclusion (day 0) and day 90.
Secondary outcomes
Both within-group and between-group analyses will be
performed for each outcome. The differences in the follow-
ing variables between the baseline (visit 1) and the last visit
(visit 3) will be calculated.
1. Barthel Index




The primary and secondary outcomes will be analyzed
using the intention to treat (ITT) method. The full ana-
lysis set for the ITT method will include all randomized
subjects, regardless of their subsequent withdrawal after
enrollment. Continuous variables will be reported as the
means ± SD, and categorical variables will be reported as
percentages. The Kolmogorov-Smirnoff test will be used
to test normality for the continuous variables, and base-
line characteristics will be compared by either Student’s
t-test/U Mann-Whitney for continuous variables or theχ2 test (Fisher’s exact test when the expected value is <5)
for categorical data.
The primary analysis for efficacy (full-analysis set) will
consist of a comparison of the change in FMMS scores at
90 days. To handle the missing data derived from with-
drawal and lost to follow-up patients, the last available out-
come measure value obtained from the withdrawn/lost to
follow-up patient will be used for the analysis (last observa-
tion carried forward (LOCF) strategy). A multiple linear re-
gression analysis will be performed to control for baseline
factors that show an imbalance.
For the within-group analyses, primary and secondary
outcome variables will be evaluated by a paired t-test. Alter-
natively, for non-normally distributed data, a Wilcoxon test
will be performed. Analysis of covariance will be used to
analyze differences in each group, adjusting for age and
NIHSS as covariates. Statistical significance will be defined
as P < 0.05. SPSS for Windows version 17.0 software (SPSS,
Inc, Chicago, IL, USA) will be used for the analyses.
Adverse event reporting
Adverse events (AEs) will be recorded in medical diagnostic
terminology. Detailed symptoms, duration, severity, causal
relationships, actions taken, results and other information
will be recorded for each AE. All AEs must be observed
and recorded in the case report file (CRF) in the AE re-
port section.
Data quality control, data collection and data
management
Data quality control will be achieved through monitoring
during the trial. After checking the written CRF, well-
trained clinical research associates of the principal investi-
gator will collect the data.
Ethical issues
This study has been approved by the institutional review
boards (IRBs) at the Centenario Hospital ‘Miguel Hidalgo’,
the Antiguo Hospital Civil de Guadalajara ‘Fray Antonio
Alcalde’ and the Hospital Regional de Alta Especialidad
‘Dr. Juan Graham Casassus’, and by the Bioethics Commit-
tee (reference: Oficio No. CB/304/11) and the Scientific
Committee (reference: Oficio No. DIC/547/11) of the
Instituto Nacional de Neurología y Neurocirugía.
Written informed consent will be obtained from each in-
dividual prior to enrollment. Research will be performed in
compliance with the Helsinki Declaration and with the
Good Clinical Practice Guidelines.
Discussion
The degree of recovery and the speed of recovery from dis-
abilities secondary to ICH are different from the recovery
of patients with CI, although this difference has rarely been
documented [19,20]. This is partly because the evidence
Marquez-Romero et al. Trials 2013, 14:77 Page 6 of 7
http://www.trialsjournal.com/content/14/1/77comes from countries where there are a disproportion-
ately lower number of patients with ICH compared with
CI available to extract adequate conclusions. However,
the existing evidence appears to demonstrate that pa-
tients with ICH recover faster and to a quantitatively
greater degree compared with patients with CI. For ex-
ample, in the study by Katrak et al. [21], even though
the studied patients with ICH had a greater level of dis-
ability at discharge, they achieved significantly greater
gains in function than patients with CI after rehabilita-
tion. This was the case regardless of the severity of dis-
ability on admission.
The study by Nannetti et al. [22], in which 20% of the
studied stroke patients suffered from ICH, patients receiv-
ing antidepressants (mostly SSRIs) made the most rapid re-
coveries during the hospital stay period. However, lower
levels of improvement were seen after discharge, which the
authors attribute to the fact that the antidepressant treat-
ment was not continued after discharge by some patients
(20.4%). This recovery was observed in the group of pa-
tients with post stroke depression (PSD) as well as in those
without PSD.
The aforementioned data indicate there is a greater
amount of potential motor recovery for patients with
ICH compared with those with CI. Still, approximately
half of ICH survivors will remain dependent on others
for daily life activities [23]. The motor recovery mecha-
nisms after stroke are still being elucidated, and most
of the studies have focused on patients with CI, so little
is known about the motor recovery mechanism for pa-
tients with ICH [24]. It has been demonstrated that the
presence of wallerian degeneration in the pyramidal
tract remote from the initial lesion on magnetic reson-
ance (MR) images correlates with a poor outcome both
in CI [25] and in ICH [26] and that the primary motor
cortex (M1) plays a key role in the motor recovery of
stroke patients. Strategies aimed to facilitate activity in
the ipsilesional M1 or to downregulate activity in the
contralesional M1 have been found to be the most useful
[27]. This ipsilesional facilitation/contralesional down-
regulation has been attempted by modulation of somato-
sensory input originating in the paretic or healthy hands.
Ipsilesional facilitation/contralesional downregulation is
also one of the apparent mechanisms of action of selective
serotonin re-uptake inhibitors (SSRIs) in the motor recov-
ery of stroke patients, in addition to cortical reorganization
and changes in the somatotopy of M1 [28].
Current guidelines recommend early supported hos-
pital discharge and home-based rehabilitation programs
as the only cost-effective intervention to aid in the
recovery of ICH patients [1]. Such interventions are
highly dependent on available resources and funding,
which make them very difficult to implement in devel-
oping countries.In Mexico, ICH accounts for nearly 30% of all stroke
cases and produces significant functional disability and
death, with 30% mortality and another 30% of patients se-
verely disabled (modified Rankin scale >3) [29]. Up to 25%
of Mexican family caregivers have to stop or cut back on
work to care for stroke survivors [30]. We strongly believe
that identification of a pharmacological intervention to aid
in the motor recovery of patients with ICH will constitute a
breakthrough that will have a major impact on the burden
of disease derived from ICH in our country. We also
theorize that the effect size should be bigger than that
found in patients with CI.
Trial status
The trial was first designed in 2011, and subject recruit-
ment began in November 2012.
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